Global Etanercept Market growing at a CAGR of 3.2% from 2023 to 2031
Category : Healthcare | Published Date : Nov 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the etanercept market is predicted to grow at a compound annual growth rate of 3.2% from 2023 to 2031 and is expected to reach USD 21,184.88 million in 2031 and 16,454.45 million in 2023 which was valued at USD 16,032.50 million in 2022.
The report highlights the increasing prevalence of autoimmune diseases is driving the market growth, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the Etanercept market.
Global Etanercept Market By Overview
The etanercept market is bifurcated into the drug type, form and application. Based on the drug type, the market is segmented into based on enbrel, benepali, and others. In 2022, the benepali segment dominates the overall etanercept market. Based on the form, the market is segmented into liquid solution and powder for injections. In 2022, the powder for injections segment dominates the overall etanercept market. Based on application, the market is segmented into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others. In 2022, the rheumatoid arthritis segment dominates the overall etanercept market.
Get Free SampleMarket Dynamics
Driver:
- Increasing prevalence of autoimmune diseases is driving the market growth.
- Growing awareness initiatives about arthritis by the government
Restraints:
- Side effects associated with utilization of etanercept.
Market Segmentation:
| Report Attributes | Report Details |
| By Drug Type | Enbrel, Benepali, and Others |
| By Form | Liquid Solution and Powder for Injections |
| By Application | Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Pfizer Limited, Amgen Inc., and Samsung Bioepis which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the etanercept market is expected to witness substantial growth in the coming years due to in increasing development of biosimilar etanercept products in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Pfizer Limited
- Amgen Inc.
- Samsung Bioepis
- AbbVie Inc
- Lupina
- Novartis
- AbbVie Inc.
